Publications (103) VICTOR MANGAS SANJUAN publications

2024

  1. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 199

  2. Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study

    Pharmaceutics, Vol. 16, Núm. 6

  3. Integrating Mechanistic and Toxicokinetic Information in Predictive Models of Cholestasis

    Journal of Chemical Information and Modeling, Vol. 64, Núm. 7, pp. 2775-2788

  4. Metodologías activas centradas en el paciente para mejorar el aprendizaje en Farmacia Clínica y Atención Farmacéutica, una asignatura esencial para iniciar en la práctica profesional

    Pharmaceutical care España, Vol. 26, Núm. 2, pp. 325-325

  5. Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis

    Pharmaceutics, Vol. 16, Núm. 10

  6. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model

    Biomedicine and Pharmacotherapy, Vol. 170

  7. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®

    Computer Methods and Programs in Biomedicine, Vol. 243

  8. Population Pharmacokinetic–Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats

    Pharmaceutics, Vol. 16, Núm. 8

  9. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Alternative Pharmacokinetic Metrics in Single-Dose Studies to Ensure Bioequivalence of Prolonged-Release Products at Steady State—A Case Study

    Pharmaceutics, Vol. 15, Núm. 2

  2. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 9, pp. 2691-2702

  3. Characterization of the interplay between different biological factors driving tumor growth dynamics in the absence of treatment.

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Commonly used methods for dissolution profile comparison

    Time-Proof Perspectives on Bioequivalence (Nova Science Publishers, Inc.), pp. 297-322

  5. Conceptos y aplicaciones de los parámetros farmacocinéticos: Una guía para el salón de clases

    Journal of Pharmacy and Pharmacognosy Research, Vol. 11, Núm. 1, pp. 160-178

  6. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid (Clinical Pharmacokinetics, (2022), 61, 6, (789-817), 10.1007/s40262-022-01125-2)

    Clinical Pharmacokinetics

  7. Desarrollo y validación de un modelo farmacocinético fisiológico para las formas ácidas y lactonizadas de atorvastatina y sus dos metabolitos

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  8. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use

    Frontiers in Pharmacology

  9. Introducción a la famacocinética

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 169-179

  10. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

  11. Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union

    Pharmaceutics, Vol. 15, Núm. 2